ESCMID weekly news 18.01.2022

18 January 2022: ESCMID Weekly
Having trouble viewing this email? View in your browser.

 

Weekly News
18 January 2022

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

Free ecraid webinar - 19 January 2022, 13:00 CET

Be sure to register for the webinar ‘How clinical trials inform antimicrobial stewardship’, which will provide an overview of data from clinical trials in the management of cUTIs and pneumonia, and how this information may be incorporated into AMS activities.

ESCMID is a proud member of ecraid.

 

 

ECCMID Keynote Highlight

We are excited to highlight the fantastic ECCMID 2022 Keynote Lecture ‘Future threats from coronaviruses’ with Malik Peiris (University of Hong Kong). See this and other highlights in the online programme, and be sure to register at the earlybird rate!

ECCMID live-sync programme launches tomorrow!

Are you looking forward to planning your experience at ECCMID 2022? Starting tomorrow (19 January), the live sync programme will be live on the ECCMID Programme website. Search sessions by type and and add them to your personal agenda to build your ECCMID experience!

DEADLINE EXTENDED – ESCMID AMS Certificate 2022 – 2024

The Antimicrobial Stewardship Certificate Programme is a newly-planned educational programme in the field of AMS. Information on how to submit a course proposal can be found here.

Submission deadline:  Friday, 28 January 2022 at 23:59 CET

Apply now for an ESCMID Funded Observership at the Mayo Clinic (US)

On January 4th the call for one ESCMID funded Observership at the Mayo Clinic (Rochester, Minnesota, USA) was opened.  Send your application today and benefit from this Observership in Summer 2022. The call is open until 27 January 2022 and is open for ESCMID Young Scientist Members only.

ECCMID online escape room – can you solve the case?

Looking for a fun Infectious Diseases-related activity? The 2021 ECCMID Virtual Escape room is now available as an interactive online game. Take part any time on the ECCMID Website, and look out for a new Escape room at ECCMID 2022!

Efficacy of favipiravir in adults with mild COVID-19

The authors conducted a randomized, double-blinded, multicenter, placebo-controlled trial in adults with mild COVID-19 to determine if favipiravir reduces the time to viral clearance. They found that favipiravir did not reduce the time to viral clearance within 15 days of starting the treatment.

 

 

 

 

Nahoru